NEW DATA ON THE PHARMACOKINETICS OF ADRIAMYCIN AND ITS MAJOR METABOLITE, ADRIAMYCINOL

被引:14
|
作者
LECA, F
MARCHISETLECA, D
NOBLE, A
ANTONETTI, M
机构
[1] Laboratoire de Pnarmacocinétique, C.H.D. Castelluccio, Ajaccio
关键词
ADRIAMYCIN; ADRIAMYCINOL; PHARMACOKINETICS;
D O I
10.1007/BF03189946
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Twenty-two days after administration by intravenous bolus, of 50 mg of adriamycin to several patients we found concentrations of adriamycin and adriamycinol of the order of 100 pcg/ml. In theory, however, with a terminal half-life of 30 h, the plasma levels of adriamycin and adriamycinol should be close to 0.1 pcg/ml. Further pharmacokinetic investigation was therefore necessary. We have retained for this study nine male patients, aged between 53 and 69 years who received 25 to 50 mg of adriamycin by slow intravenous injection. The HPLC method permitted the detection of 50 pcg/ml of adriamycin and adriamycinol, with the possibility of monitoring their elimination during 120 h (and in one case during 160 h). The terminal half-lives of elimination estimated in 8 patients were respectively 110 +/- 52 h for adriamycin and 92 h 50 min +/- 43 h for adriamycinol. Surface ratios under adriamycinol curves against calculated adriamycin was 1.10 +/- 0.26. Plasma levels found during the To in certain patients correspond to the end of the drug elimination of the previous treatment. It is difficult with a half-life to 110 h to predict the effects of residual concentrations of adriamycin and adriamycinol.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF METHSUXIMIDE AND A MAJOR METABOLITE IN DOGS
    DOBRINSKA, MR
    WELLING, PG
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (05) : 688 - 692
  • [22] Comparison of the pharmacokinetics of Dolasetron and its major active metabolite, reduced dolasetron, in dog
    Dow, J
    DiFrancesco, GF
    Berg, C
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (07) : 685 - 689
  • [23] Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats
    Hyun Jin Choi
    Jun-Shik Choi
    Archives of Pharmacal Research, 2005, 28 : 970 - 976
  • [24] PHARMACOKINETICS AND ANTI-DICRODOELIUM EFFECT OF THIOPHANATE AND ITS MAJOR METABOLITE IN RUMINANTS
    DELATOUR, P
    BESSE, S
    ROMDANE, MN
    ANNALES DE RECHERCHES VETERINAIRES, 1988, 19 (02): : 119 - 122
  • [25] Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats
    Hyun Jin Choi
    Jun Shik Choi
    Archives of Pharmacal Research, 2006, 29 : 935 - 935
  • [26] Sequential Modeling of the Population Pharmacokinetics of Revefenacin and its Major Metabolite in COPD Patients
    Lo, Arthur
    Borin, Marie T.
    Bourdet, David L.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S9 - S9
  • [27] THE PHARMACOKINETICS AND HEMODYNAMICS OF BTS 49465 AND ITS MAJOR METABOLITE IN HEALTHY-VOLUNTEERS
    WYNNE, RD
    CRAMPTON, EL
    HIND, ID
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (06) : 659 - 664
  • [28] Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats
    Liao, Sha
    Jin, Xueyuan
    Li, Jinglai
    Zhang, Tianhong
    Zhang, Wenpeng
    Shi, Weiguo
    Fan, Shiyong
    Wang, Xiaoying
    Wang, Juan
    Zhong, Bohua
    Zhang, Zhenqing
    PHYTOTHERAPY RESEARCH, 2016, 30 (04) : 618 - 626
  • [29] Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment
    Pitsiu, M
    Wilmer, A
    Bodenham, A
    Breen, D
    Bach, V
    Bonde, J
    Kessler, P
    Albrecht, S
    Fisher, G
    Kirkham, A
    BRITISH JOURNAL OF ANAESTHESIA, 2004, 92 (04) : 493 - 503
  • [30] PHARMACOKINETICS OF TETRABENAZINE AND ITS MAJOR METABOLITE IN MAN AND RAT - BIOAVAILABILITY AND DOSE DEPENDENCY STUDIES
    MEHVAR, R
    JAMALI, F
    WATSON, MWB
    SKELTON, D
    DRUG METABOLISM AND DISPOSITION, 1987, 15 (02) : 250 - 255